AB Science has a unique and diversified indication portfolio that includes multiple late-stage programs.

Compound

Therapeutic area

Indication

Preclinical

Phase 1

Phase 2

Phase 2B/3

Confirmatory Phase 3

NDA/MAA

Masitinib

AB8939

Neurology
Diseases

Inflammatory
Diseases

Oncology

Viral
Diseases

Oncology

Amyotrophic Lateral Sclerosis*

Progressive forms of Multiple Sclerosis*

Alzheimer’s Disease*

Indolent Systemic Mastocytosis*

MCAS (mast cell activation syndrome)

Severe Asthma Uncontrolled with OCS*

Severe Asthma Uncontrolled with ICS*

Pancreatic Cancer*

Metastatic Prostate Cancer*

Moderate and Severe COVID-19 (anti-inflammatory)

Mild and moderate COVID-19 (anti-viral)

Acute Myeloid Leukemia

2022_11_pipeline_Mobile_EN

* Positive Phase 2B/3 Results Reported